

1 **Detection of SARS-CoV-2 RNA by direct RT-qPCR on nasopharyngeal specimens without**  
2 **extraction of viral RNA**

3  
4 Mohammad Rubayet Hasan<sup>1,2</sup>, Faheem Mirza<sup>1</sup>, Hamad Al-Hail<sup>1</sup>, Sathyavathi Sundararaju<sup>1</sup>,  
5 Thabisile Xaba<sup>1</sup>, Muhammad Iqbal<sup>1</sup>, Hashim Alhussain<sup>3</sup>, Hadi Mohamad Yassine<sup>3</sup>, Andres Perez  
6 Lopez<sup>1,2</sup>, Patrick Tang<sup>1,2</sup>

7  
8 <sup>1</sup>Department of Pathology, Sidra Medicine; <sup>2</sup>Weill Cornell Medical College in Qatar, Doha, Qatar;  
9 <sup>3</sup>Qatar University, Doha, Qatar

10 **Short title:** SARS-CoV-2 detection by RT-qPCR without RNA extraction

11  
12 **Corresponding author:**

13 Mohammad Rubayet Hasan, PhD, FCCM, D(ABMM)

14 Clinical Molecular Microbiologist, Department of Pathology

15 Assistant Professor of Clinical Pathology and Laboratory Medicine

16 Weill Cornell Medical College in Qatar (WCMC-Q)

17 Sidra Medicine

18 Office no: H2M-24093

19 PO Box 26999, Doha, Qatar

20 Direct: +974 4003 2996

21 Mobile: +974 3003 5501

22 [mhasan@sidra.org](mailto:mhasan@sidra.org) / <http://www.sidra.org/doctors/mohammad-rubayet-hasan/>

23

24 **Abstract**

25 To circumvent the limited availability of RNA extraction reagents, we aimed to develop a  
26 protocol for direct RT-qPCR to detect SARS-CoV-2 in nasopharyngeal swabs without RNA  
27 extraction. Nasopharyngeal specimens positive for SARS-CoV-2 and other coronaviruses  
28 collected in universal viral transport (UVT) medium were pre-processed by several commercial  
29 and laboratory-developed methods and tested by RT-qPCR assays without RNA extraction using  
30 different RT-qPCR master mixes. The results were compared to that of standard approach that  
31 involves RNA extraction. Incubation of specimens at 65°C for 10 minutes along with the use of  
32 TaqPath™ 1-Step RT-qPCR Master Mix provides higher analytical sensitivity for detection of  
33 SARS-CoV-2 RNA than many other conditions tested. The optimized direct RT-qPCR approach  
34 demonstrated a limit of detection of  $6.6 \times 10^3$  copy/ml and high reproducibility (co-efficient of  
35 variation = 1.2%). In 132 nasopharyngeal specimens submitted for SARS-CoV-2 testing, the  
36 sensitivity, specificity and accuracy of our optimized approach were 95%, 99% and 98.5%,  
37 respectively, with reference to the standard approach. Also, the RT-qPCR  $C_T$  values obtained by  
38 the two methods were positively correlated (Pearson correlation coefficient  $r=0.6971$ ,  $p=0.0013$ ).  
39 The rate of PCR inhibition by the direct approach was 8% compared to 9% by the standard  
40 approach. Our simple approach to detect SARS-CoV-2 RNA by direct RT-qPCR may help  
41 laboratories continue testing for the virus despite reagent shortages or expand their testing  
42 capacity in resource limited settings.

43

44

45

## 46 **Introduction**

47           The ongoing pandemic of coronavirus disease (COVID-19) caused by a novel  
48 coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posed an  
49 unprecedented public health threat to the entire world. In the absence of an effective vaccine or  
50 specific treatment against the virus, early detection and contact tracing, physical distancing  
51 measures and quarantine of cases are considered the cornerstones to curb the community  
52 transmission of SARS-CoV-2 [1-3]. Since the virus was identified and its genome sequenced in  
53 early January 2020, detection of viral RNA in respiratory specimens by real-time reverse  
54 transcription PCR (RT-qPCR) remains the main approach to manage the outbreak by allowing  
55 early detection of cases and targeted measures to prevent transmission of the virus [4]. The  
56 massive demand for SARS-CoV-2 RT-qPCR has brought about a global shortage and supply  
57 chain irregularities of RNA extraction kits that are crucial for RT-qPCR testing [5-7]. In this  
58 study, we tested a number of commercial and laboratory-developed, specimen pre-treatment  
59 procedures to optimize the performance of direct RT-qPCR for SARS-CoV-2 avoiding the RNA  
60 extraction step. This method was validated against a standard approach that included extraction  
61 of viral RNA on a commercial automated extraction platform.

62

## 63 **Materials and methods**

64           Standard approach for detection of SARS-CoV-2 RNA from nasopharyngeal specimens  
65 in our laboratory involves extraction of total nucleic acids from specimens in an IVD-labeled,  
66 automated extraction platform followed by RT-qPCR, based on one of the assays (Table 1)  
67 suggested by World Health Organization (WHO)[8]. The performance standards of the assay  
68 were established in our laboratory according to College of American Pathologists (CAP)

69 standards, and at time of writing this paper, the assay was used to test more than 2000 respiratory  
70 specimens to screen patients for potential infection with SARS-CoV-2. Therefore, the assay was  
71 used as the reference method for all other alternative approaches assessed in this study. All  
72 specimen preparations, pre-treatments and PCR setup were performed in a Class II Biosafety  
73 cabinet in a Biosafety level 2 (BSL2) facility.

74       Clinical specimens: Nasopharyngeal flocculated swab (NPFS) specimens collected in  
75 universal viral transport (UVT) medium (Becton, Dickinson and Company) (n= 150) submitted  
76 for testing SARS-CoV-2 or other respiratory viruses at Sidra Medicine, Doha, Qatar were used in  
77 this study. To maintain patient anonymity, each sample was coded, and all patient identifiers  
78 were removed to ensure that personnel involved in this study were unaware of any patient  
79 information. Ethics approval was not sought because the study involves laboratory validation of  
80 test methods and the secondary use of anonymous pathological specimens that falls under the  
81 category ‘exempted’ by Sidra Medicine Institutional Review Board. For spiking experiments,  
82 NPFS specimens (n=6) were collected from laboratory volunteers after obtaining written  
83 informed consents. No personal data were collected, and specimens were labeled with random  
84 numbers so that test results cannot be linked to an individual.

85       Nucleic acid extraction: Nucleic acids from 0.2 ml of NPFS specimens were extracted on  
86 a NucliSENS® easyMAG platform (bioMérieux, France) according to the methods described by  
87 the manufacturers.

88       Pre-treatment of specimens: Unless otherwise stated, specimens were diluted using  
89 nuclease free water. Heat treatment of specimens at different temperature was performed in a  
90 ThermoMixer (Eppendorf). Specimens processed with Arcis Coronavirus RNA extraction  
91 research kit (Arcis Biotechnology) were performed according to manufacturer’s instructions.

92 Briefly, 90 µl specimen was mixed with 6 µl Reagent 1 RTU and either left unheated or heat  
93 lysed at 60°C for 5 minutes. 40 µl of lysate was then mixed with 2 µl of Reagent 2a and was used  
94 directly for Rt-qPCR. For Takara PrimeDirect™ Probe RT-qPCR Mix (Takara Bio), 0.2 ml  
95 specimens were heated at 99°C for 10 mins and then centrifuged at 4000rpm for 5 min. The  
96 supernatants were collected and 7µl of supernatant was directly used in RT-qPCR reaction  
97 mixture.

98 RT-qPCR: Primers and probes for detection of SARS-CoV-2, HCoV-HKU1 and MS2  
99 bacteriophage are listed in Table S1 [4,9,10]. For detection of HCoV-HKU1 using Quantifast  
100 Pathogen RT-PCR + IC kit (Qiagen), five µl of extracted or pre-treated samples were mixed with  
101 20 µl of a master mix containing 5 µl of Quantifast Pathogen RT-PCR + IC Master Mix, 0.25 µl  
102 of Quantfast RT Mix and 0.5 µl of 50 x ROX dye solution and primers and probes to final  
103 concentrations shown in Table S1. Thermal cycling was performed in a ABI7500 Fast instrument  
104 (Thermofisher Scientific) with 1 cycle of reverse transcription at 50°C for 20 min followed by 1  
105 cycle of PCR activation at 95°C for 5 min, followed by 40 amplification cycles each consisting  
106 of 95°C-15s and 60°C-60s. For detection of HCoV-HKU1 using TaqPath™ 1-Step RT-qPCR kit  
107 (Thermofisher Scientific), five µl of extracted or pre-treated samples were mixed with 5 µl of a  
108 master mix containing 5 µl of TaqPath™ 1-Step RT-qPCR Master Mix and primers and probes  
109 to final concentrations shown in Table S1. Thermal cycling was performed in a ABI7500 Fast  
110 instrument (Thermofisher Scientific) with 1 cycle of reverse transcription at 50°C for 15 min  
111 followed by 1 cycle of polymerase activation at 95°C for 2 min, followed by 40 amplification  
112 cycles each consisting of 95°C-15s and 60°C-60s.

113 For detection of SARS-CoV-2 with standard method, five µl of nucleic acid extracts from  
114 NucliSENS® easyMAG system were mixed with 7.5 µl of a master mix containing 2.5 µl of

115 Quantifast Pathogen RT-PCR + IC Master Mix, 0.125  $\mu$ l of Quantfast RT Mix and 0.25  $\mu$ l of 50  
116 X ROX dye solution and primers and probes to final concentrations shown in Table S1. RNA  
117 extraction and PCR inhibition were monitored by an internal control PCR assay, using the  
118 primers and probes shown in Table S1. Specimens were spiked with a tittered preparation of  
119 MS2 bacteriophage to serve as a template for internal control assay. For direct PCR on  
120 specimens, pre-treated specimens were assessed in the same way except that extracted MS2  
121 bacteriophage RNA was mixed with PCR master mix to serve as an inhibition control. A  
122 synthetic RNA (IDT) based on E-Sarbeco assay [4] amplicon sequence was used as a positive  
123 control. As negative control, 0.2 ml neonatal calf serum (NCS) (Thermofisher Scientific) was  
124 extracted along with specimens and used with each PCR run. SARS-CoV-2 RT-qPCR with  
125 Takara PrimeDirect™ Probe RT-qPCR Mix was performed as described by the manufacturer.  
126 Briefly, 7  $\mu$ l of processed samples were mixed with 18  $\mu$ l of master mix containing 12.5  $\mu$ l of  
127 PrimeDirect Probe RT-qPCR Mix and primers and probes to final concentrations shown in Table  
128 1. Thermal cycling was performed in a ABI7500 Fast instrument (Thermofisher Scientific) with  
129 1 cycle of denaturation at 96°C for 10 sec, 1 cycle of reverse transcription at 60°C for 5 min  
130 followed by 45 amplification cycles each consisting of 95°C-5s and 60°C-30s. SARS-CoV-2  
131 RT-qPCR with TaqPath™ 1-Step RT-qPCR kit with the optimized approach (specimens heat  
132 treated at 65°C for 10 min) was performed as above except that 8  $\mu$ l of specimen was used per 20  
133  $\mu$ l reaction.

134 A total of 132 NPS that were previously tested by the standard approach were also tested  
135 by the optimized, direct approach and the results were compared. In addition, an external quality  
136 assessment (EQA) panel (8 specimens) from Quality Control for Molecular Diagnostics  
137 (QCMD) was tested simultaneously with the standard and the direct approach, as well as with a

138 QIAstat-Dx Respiratory 2019-nCoV Panel (Qiagen) and the results were compared with  
139 expected results.

140 Limit of detection (LOD) study: A SARS-CoV-2 positive nasopharyngeal specimen ( $C_T$   
141 = 23.3) was titered by the optimized approach using synthetic RNA, and serially diluted (up to  
142  $5 \times 10^{-7}$  - fold) using a negative specimen. All diluted specimens were pre-treated by heating at  
143  $65^\circ\text{C}$  for 10 min and then assessed by SARS-CoV-2 RT-qPCR in replicates of 8. The  $C_T$  values  
144 obtained were used to calculate limit of detection (LOD) and intra-assay reproducibility of direct  
145 RT-qPCR.

146 Statistical analysis: Sensitivity, defined as the number of true positive results divided by  
147 the sum of true positive and false negative results; specificity, defined as the number of true  
148 negative results divided by the sum of true negative and false positive results; and accuracy  
149 (concordance), defined as the sum of true positive and true negative results divided by the total  
150 number of test samples, were calculated and expressed as percentages. Ninety-five percent  
151 confidence intervals (CI) for sensitivity, specificity and accuracy were calculated by the Clopper-  
152 Pearson interval or exact method using an online, diagnostic test evaluation calculator (MedCalc,  
153 2018). Correlation between the RT-qPCR  $C_T$  values between standard approach and optimized  
154 direct approach was determined by Pearson's coefficient calculator. The limit of detection with  
155 95% endpoint ( $C_{95}$ ) was determined by Probit regression analysis [11].

156

## 157 **Results**

158 Using a human coronavirus HKU1 (hCoV-HKU1) positive specimen as a surrogate for  
159 SARS-CoV-2, we first assessed whether specimens can be used directly for RT-qPCR after 2-10  
160 fold dilution with nuclease free water (NFW), simple heat treatment ( $100^\circ\text{C}$  for 5 min) and

161 centrifugation to remove any insoluble material that may be present in the specimen. The pre-  
162 treated specimens were then assessed in parallel with extracted specimens by a previously  
163 described, laboratory developed RT-qPCR for HCoV-HKU1 (Table S1). A significant loss of  
164 sensitivity was observed with a RT-qPCR  $\Delta C_T$  ranging from 10-14 (Table S2). To determine  
165 whether any components of UVT medium (Becton, Dickinson and Company) were inhibitory to  
166 RT-qPCR, we collected nasopharyngeal flocked swabs (NPFS) from laboratory volunteers in  
167 NFW along with swabs in UTM. We then spiked a SARS-CoV-2 positive specimen to all  
168 specimens and assessed them by SARS-CoV-2 RT-qPCR. However, no significant improvement  
169 in sensitivity was observed (Table S3).

170         Similar results were observed when two commercial test kits were used for direct RT-  
171 qPCR: Arcis Coronavirus RNA extraction research kit comes with lysis reagents that can be used  
172 directly in RT-qPCR; and Takara PrimeDirect™ Probe RT-qPCR kit provides a master mix that  
173 is compatible with heat-treated specimen extracts. However, in our evaluation both test kits  
174 failed to demonstrate an acceptable level of sensitivity (Tables S4 and S5). Our attempts to  
175 further optimize the pre-treatment conditions showed modest improvement with a non-ionic  
176 detergent, Tween-20, and further improvement with a heating step at 65°C for 10 min without  
177 centrifugation ( $\Delta C_T = 5.2$ ) (Table S6). We then tested this low heat approach with more SARS-  
178 CoV-2 positive specimens and using 3 different RT-qPCR master mixes. Interestingly, we found  
179 that with TaqPath™ 1-Step RT-qPCR Master Mix, 4/4 positive samples were correctly detected  
180 with a  $\Delta C_T$  range 0.8 – 3.8 (Table 1). On the other hand, two other master mixes gave higher  $\Delta C_T$   
181 and 1/4 positive results were missed by both. Based on these results, the optimal pre-treatment  
182 and reaction conditions for the direct approach were: i) transfer and dilute (4-fold) 10  $\mu$ l of NPFS



183 specimen in NFW; ii) incubate at 65°C for 10 min; and iii) test 8 µl of heat lysed specimen in a  
184 20 µl reaction using TaqPath™ 1-Step RT-qPCR Master Mix.

185 The analytical sensitivity of the direct RT-qPCR assay using specimens prepared in this  
186 manner was determined by serially diluting a specimen positive for SARS-CoV-2 with a  
187 negative specimen as a diluent. The positive specimen was titered based on the  $C_T$  value  
188 obtained by the direct approach using a standard curve prepared with SARS-CoV-2 synthetic  
189 RNA. The  $C_T$  values were linear ( $R^2 = >0.99$ ) over the range of  $10^3$  copy/ml to  $10^8$  copy/ml, the  
190 highest concentration used in this analysis (Fig. 1A and 1B). The 95% limit of detection (LOD;  
191  $C_{95}$ ) of the assay with the direct approach was  $6.6 \times 10^3$  copy/ml. The  $C_T$  variation between RT-  
192 qPCR replicates across different concentration of analytes were  $<1$  with an average coefficient of  
193 variation (CV%) of 1.2%.

194 A total of 132 NPFS specimens that were previously tested with standard approach  
195 including viral RNA extraction were re-tested with the new direct approach. The direct approach  
196 detected all except one positive case with  $C_T > 38$ . On the other hand, the direct approach detected  
197 ( $C_T > 37$ ) SARS-CoV-2 in one specimen that was negative by standard approach. Overall  
198 agreement of results between two approaches was  $>98\%$  (Kappa= 0.939; 95% CI = 0.854 to  
199 1.000). The sensitivity and specificity of the new approach compared to the reference method  
200 were 95% and 99%, respectively (Table 2). The RT-qPCR  $C_T$  values for all specimens that were  
201 positive by both methods (n=18) were positively correlated with a Pearson coefficient (R) of  
202 0.6971 ( $p < 0.01$ ) (Fig. 2). The rate of PCR inhibition among the specimens that gave negative  
203 RT-qPCR results by the direct approach was 8% compared to 9% by the standard approach.  
204 Finally, the direct approach accurately detected SARS-CoV-2 RNA in all except one specimen in  
205 an external quality assessment (EQA) panel provided by Quality Control for Molecular

206 Diagnostics (QCMD)(Table S7). The specimen that gave discrepant result was reported as  
207 ‘borderline’ by QCMD, and SARS-CoV-2 RNA was also undetectable in this specimen by  
208 standard approach and by a commercial test, QIAstat-Dx Respiratory 2019-nCoV Panel  
209 (Qiagen).

210

## 211 **Discussion**

212 Success in RT-qPCR testing depends on multiple factors. RNA extraction is preferable to  
213 the use of direct specimens because the extraction process concentrates and purifies the RNA  
214 targets and excludes PCR inhibitory substances. The use of pre-treated or untreated specimens  
215 directly in RT-qPCR is challenging because of the presence of inhibitors and RNA loss due to  
216 heating and/or RNases. After many attempts with various pre-treatment agents and conditions,  
217 we have determined an optimal pre-treatment protocol complemented with specific RT-qPCR  
218 reagents, that generates results equivalent to standard methods that involve RNA extraction.  
219 Minimizing RNA loss through the low heat approach, appropriate dilution of inhibitory  
220 substances and the higher sensitivity of TaqPath™ 1-Step RT-qPCR Master Mix may have  
221 played a combinatory role in achieving equivalency of the direct RT-qPCR compared to a  
222 standard approach requiring viral RNA extraction.

223 In summary, our new approach demonstrated high sensitivity and specificity in the  
224 detection of SARS-CoV-2 RNA, and the rate of RT-qPCR inhibition was similar to that of a  
225 standard approach. By skipping the RNA extraction step, the new approach will also  
226 significantly reduce the cost and improve the turn-around time of the assay. Delayed and  
227 inadequate laboratory testing can significantly hamper efforts to control the pandemic. Our  
228 results will help many labs all over the world who are struggling with a shortage of reagents to

229 continue testing for SARS-CoV-2. Also, because of a significant reduction in cost, the optimized  
230 direct approach we described, will be useful to resource-limited countries to expand their  
231 capacity for RT-qPCR testing.

232

### 233 **Acknowledgement**

234 We are grateful for the efforts of all technologists in the Molecular Infectious Disease Laboratory  
235 at Sidra Medicine.

### 236 **References**

- 237 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et. Al. A Novel Coronavirus from  
238 Patients with Pneumonia in China, N Engl J Med 2019;382(8):727-733.
- 239 2. Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health  
240 Organization declares global emergency: A review of the 2019 novel coronavirus  
241 (COVID-19). Int J Surg 2020;76:71-76.
- 242 3. Steffens I. A hundred days into the coronavirus disease (COVID-19) pandemic,  
243 Eurosurveillance. [https://www.eurosurveillance.org/content/10.2807/1560-](https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.14.20005550#r8)  
244 [7917.ES.2020.25.14.20005550#r8](https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.14.20005550#r8). Accessed 18 April 2020.
- 245 4. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of  
246 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25(3).
- 247 5. Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators  
248 and Personal Protective Equipment during the Covid-19 Pandemic. N Engl J Med  
249 2020;doi: 10.1056/NEJMp2006141.

- 250 6. Slabodkin G. FDA chief warns of supply 'pressure' on reagents for coronavirus tests.  
251 [https://www.medtechdive.com/news/fda-chief-warns-of-supply-pressure-on-reagents-for-](https://www.medtechdive.com/news/fda-chief-warns-of-supply-pressure-on-reagents-for-coronavirus-tests/573999/)  
252 [coronavirus-tests/573999/](https://www.medtechdive.com/news/fda-chief-warns-of-supply-pressure-on-reagents-for-coronavirus-tests/573999/). Accessed 18 April 2020.
- 253 7. Yan Y, Chang L, Wang L. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-  
254 CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. *Rev Med Virol*  
255 2020;17:e2106.
- 256 8. World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic.  
257 Geneva: WHO. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.  
258 Accessed 18 April 2020.
- 259 9. Hasan MR, Al Mana H, Young V, Tang P, Thomas E, Tan R, et al. A novel real-time  
260 PCR assay panel for detection of common respiratory pathogens in a convenient, strip-  
261 tube array format. *J Virol Methods* 2019;265:42-48.
- 262 10. Dreier J, Stormer M, Kleesiek K. Use of bacteriophage MS2 as an internal control in viral  
263 reverse transcription-PCR assays. *J Clin Microbiol* 2005;43:4551-7.
- 264 11. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases.  
265 *Clin Microbiol Rev* 2010;23(3):550-576.

266

267

268

269

270

271

272 Table 1: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens after heating  
 273 at 65°C for 10 minutes with different RT-qPCR master mixes

Sample No.	SARS-CoV-2 C <sub>T</sub>			
	Standard method	Quantifast Pathogen RT-PCR + IC Master Mix	PrimeDirect™ Probe RT-qPCR Mix	TaqPath™ 1-Step RT-qPCR Master Mix
1	21.5	29.4	24.6	22.8
2	34.5	Undetermined	Undetermined	35.3
3	24.5	30.4	28.7	25.5
4	22	29.9	31.4	25.8
5	Undetermined	Undetermined	Undetermined	Undetermined

274  
 275 NPFS specimens were either subjected to viral RNA extraction by standard method using the  
 276 NucliSENS easyMAG automated extraction system (bioMerieux), or diluted 4-fold with NFW  
 277 followed by incubation at 65°C for 5 minutes. All samples were tested for SARS-CoV-2 RNA by  
 278 standard RT-qPCR using different master mixes in duplicate and mean C<sub>T</sub> values were  
 279 compared.

280

281 Table 2: Performance of optimized direct RT-qPCR approach with reference to standard  
282 approach for detection of SARS-CoV-2 RNA

283

Statistic	Value	95% CI
Total number of specimens	132	-
True positive	18	-
True negative	112	-
False positive	1	-
False negative	1	-
Sensitivity	95.0%	74% to 99.8%
Specificity	99.0%	95.2% to 99.9%
Accuracy	98.5%	94.6% to 99.8%

284

285

286

287

288

289

290

291

292 **Figure legends**

293 Figure 1: Linearity of SARS-CoV-2 RT-qPCR by direct approach. A tittered SARS-CoV-2  
294 positive nasopharyngeal specimen was serially diluted using a negative specimen, pre-heated at  
295 65°C for 10 min and assessed by SARS-CoV-2 RT-qPCR as described in the Supplemental  
296 methods. A) Amplification curves from SARS-CoV-2 RT-qPCR assay on the serially diluted  
297 sample. B) RT-qPCR  $C_T$  values were plotted against estimated copy number of SARS-CoV-2  
298 RNA in each dilution. Each data point represents an average of data obtained from 8 replicates.

299

300 Figure 2: Correlation of RT=qPCR  $C_T$  values obtained by direct versus standard approach.

301

302

303

304

305

306

307

308

309

310

311 Figure 1

312

313


314

315


316

317

318



B)



319

320

321

322

323

324

325

326

327



328 Figure 2

329

330


331

332

333

334

335



336

337

338

339

340

341

342

343

344

345 **Supplemental Tables**

346

347 Table S1: Primers and probes used in this study

Assay	Target	Name	Sequence (5'-3')	5'-Label	3'-Label	Final concentration (μM)	Source
		HCoV-HKU1-F	GATCCTACTAYTCAAGAAG CTATCCCTACT			0.6	
HCoV-HKU1	Nucleocapsid gene	HCoV-HKU1-R	ACCTTCCTGAGCCTTCAAC ATAAT			0.3	(1)
		HCoV-HKU1-P	TTYCYGCCTGGTACGATTTT GCCTC	JOE/ZEN	IaBkFQ	0.2	
		E_Sarbeco_F1	ACAGGTACGTTAATAGTTA ATAGCGT			0.4	
	E gene	E_Sarbeco_R2	ATATTGCAGCAGTACGCAC ACA			0.4	(2)
SARS-CoV-2		E_Sarbeco_P1	ACACTAGCCATCCTTACTG CGCTTCG	FAM/ZEN	IaBkFQ	0.2	
		MS2-TM3-F	GGCTGCTCGCGGATACCC			0.2	
	Internal control	MS2-TM3-R	TGAGGGAATGTGGGAACCG			0.2	(3)
		MS2-TM2JOE	ACCTCGGGTTTCCGTCTTG CTCGT	JOE/ZEN	IaBkFQ	0.1	

348

349

350

351

352

353

354

355

356

357

358

359 Table S2: Direct RT-qPCR on a nasopharyngeal specimen positive for human coronavirus HKU1 after  
 360 heat treatment at 100°C for 5 minutes

361

Sample Name	Sample dilution	Sample processing	HKU1 CoV C <sub>T</sub>	
			Quantifast Pathogen RT-PCR + IC Master Mix	TaqPath™ 1-Step RT-qPCR Master Mix
1167-H0	Undiluted	easyMAG extraction	24.6	23.8
1167-H1	Undiluted	Heat treatment	36.4	36.6
1167-H2	2 fold dilution	Heat treatment	34.5	35.7
1167-H3	4 fold dilution	Heat treatment	34.7	35.6
1167-H4	10 fold dilution	Heat treatment	34.1	33.2
1167-H5	Undiluted	Freeze thaw; heat treatment	38.1	36.1

362

363 NPFS specimens were either i) subjected to viral RNA extraction by standard method using a NucliSENS  
 364 easyMAG automated extraction system (Biomerieux), or ii) serially diluted with nuclease free water  
 365 (NFW) followed by incubation at 100°C for 5 minutes, or iii) freeze thawed once prior to heat treatment.  
 366 All heat-treated samples were centrifuged at 13,000 rpm for 5 minutes at 4°C and supernatants were  
 367 collected. All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR in duplicate and mean  
 368 C<sub>T</sub> values were compared.

369

370

371

372

373

374

375

376

377 Table S3: Direct RT-qPCR on simulated, dry NPFS using a spiked specimen positive for SARS-CoV-2

Sample No.	SARS-CoV-2 C <sub>T</sub>	
	Standard method	Direct PCR on dry NPFS
1	20.8	32.4
2	20.5	25.8
3	20.8	32.4
4	25.7	31.6
5	25.8	33.8
6	25.6	34.5

378

379 Specimens were collected from laboratory members who volunteered to provide specimens. NPFS  
380 specimens were either i) collected in VTM or ii) collected in sterile empty tubes as dry swabs and later  
381 resuspended in 1 ml of NFW. Five µl of a patient specimen positive for SARS-CoV-2 RNA (C<sub>T</sub> = 22)  
382 were spiked into 0.2 ml of specimens collected in VTM of NFW. VTM specimens were extracted by  
383 standard method using a NucliSENS easyMag automated extraction system (bioMerieux). Specimens  
384 collected in NFW were incubated at 100°C for 5 minutes and centrifuged at 13,000 rpm for 5 minutes at  
385 4°C and supernatants were collected. All samples were tested for SARS-CoV-2 RNA by standard RT-  
386 qPCR using Quantifast Pathogen RT-PCR + IC Master Mix in duplicate and mean C<sub>T</sub> values were  
387 compared.

388

389

390

391

392

393

394

395

396

397

398

399 Table S4: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens processed using  
400 Arcis Pathogen Kit

401

Sample No.	SARS-CoV-2 C <sub>T</sub>		
	Standard method	Arcis kit with heating	Arcis kit - no heating
1	Undetermined	Undetermined	Undetermined
2	Undetermined	Undetermined	Undetermined
3	Undetermined	Undetermined	Undetermined
4	25.0	34.9	33.5
5	21.0	32.9	Undetermined
6	23.0	28.4	32.3

402

403 NPFS specimens were processed according to manufacturer's protocol (Arcis Biotechnology Ltd.). All  
404 samples were tested for SARS-CoV-2 RNA by standard RT-qPCR in duplicate and mean C<sub>T</sub> values were  
405 compared.

406

407

408

409

410

411

412

413

414

415

416

417

418 Table S5: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens processed using  
419 Takara

420

Sample No.	SARS-CoV-2 C <sub>T</sub>	
	Standard method	Takara PrimeDirect protocol
1	21.5	29.78692245
2	34.5	Undetermined
3	24.5	Undetermined
4	33.7	Undetermined
5	Undetermined	Undetermined

421

422 NPFS specimens were processed according to manufacturer's protocol (PrimeDirect™ Probe RT-qPCR  
423 Mix, Takara Bio Inc.). All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR in duplicate  
424 and mean C<sub>T</sub> values were compared.

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439 Table S6: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens with or without  
440 heating at 65°C for 5 minutes or after lysis using a non-ionic detergent

441

Sample No.	SARS-CoV-2 C <sub>T</sub>			
	Standard method	No treatment	Heat treatment	Lysis with 0.2% Tween-20
1	21.5	30.6	26.7	28.4
2	34.5	Undetermined	Undetermined	Undetermined
3	Undetermined	Undetermined	Undetermined	Undetermined
4	Undetermined	Undetermined	Undetermined	Undetermined
5	Undetermined	Undetermined	Undetermined	Undetermined

442

443 NPFS specimens were either i) subjected to viral RNA extraction by standard method using a NucliSENS  
444 easyMAG automated extraction system (bioMerieux), or ii) diluted 4-fold with nuclease free water  
445 (NFW) iii) diluted 4-fold with nuclease free water (NFW) followed by incubation at 65°C for 5 minutes  
446 or iv) diluted 4-fold with Tween-20 to final concentration of 0.2% followed by incubation at room  
447 temperature for 10 min. All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR using  
448 Quantifast Pathogen RT-PCR + IC Master Mix.

449

450

451

452

453

454

455

456

457

458

459

460

461 Table S7: Direct RT-qPCR on QCMD EQA specimens

462

Sample No.	QCMD result	SARS-CoV-2 C <sub>T</sub>		
		Standard approach	QIAstat	Direct approach
Sample 1	Positive	33.4	34	35.5
Sample 2	Negative	undetermined	undetermined	Undetermined
Sample 3	Positive	35.2	35.4	37.1
Sample 4	Negative	undetermined	undetermined	Undetermined
Sample 5	Negative	undetermined	undetermined	Undetermined
Sample 6	Positive	34.2	36.7	35.1
Sample 7	Positive	29.4	31.5	31.7
Sample 8	Borderline	undetermined	undetermined	Undetermined

463

464 QCMD EQA specimens were simultaneously tested by standard and direct approach and by QIAstat-Dx  
465 Respiratory 2019-nCoV Panel (Qiagen)

466

467

468

469

470

471

472

473

474